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Objectives: Spasticity is a common and disabling feature of amyotrophic lateral scle-
rosis (ALS). There are currently no validated ALS- specific measures of spasticity. The 
aim of this study was to develop and use a self- report outcome measure for spasticity 
in ALS.
Methods: Following semi- structured interviews with 11 ALS patients, a draft scale 
was administered across ALS clinics in the UK. Internal validity of the scale was ex-
amined using the Rasch model. The numerical rating scale (NRS) for spasticity and 
Leeds Spasticity scale (LSS) were co- administered. The final scale was used in a path 
model of spasticity and quality of life.
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1  | INTRODUC TION
Spasticity is a key feature in amyotrophic lateral sclerosis/motor 
neurone disease (ALS/MND) and its subtype primary lateral sclero-
sis. Patients affected by spasticity experience stiffness, spasms and 
difficulty with fine motor control. Although a predominant symp-
tom of this disease, there is limited information on the epidemiology, 
clinical characteristics and treatment of spasticity in ALS. Previous 
research has shown that spasticity may affect ALS patients in dis-
tinct ways compared to other neurological disorders.1 For example, 
people with ALS may experience recurrent bulbar spasticity which 
is particularly distressing as breathing and speech are interrupted.
The assessment of the effectiveness of spasticity treatments 
has been a contentious issue, and gold standard measures are lack-
ing. The Ashworth and modified Ashworth scales are the most 
widely used clinical methods to assess spasticity but have recently 
been questioned due to concerns over validity, reliability and re-
sponsiveness.2,3 Studies have shown that findings on examination 
performed by a clinician do not always correlate with the patient’s 
symptoms regarding severity and location of spasticity, and there is 
evidence that the Ashworth scale might not represent the patients’ 
experience of spasticity.4,5 For example, as the Ashworth scale is a 
measure of passive muscle resistance, it cannot be used to assess 
spasticity- related spasms, which can be severe and debilitating for 
patients. As a result, there has been a growing interest in develop-
ing tools that measure spasticity from patients’ perspectives across 
a variety of neurological conditions, to help clinicians understand 
and adequately treat spasticity and spasticity- related symptoms. 
Patient reported outcome measures (PROMs) such the Multiple 
Sclerosis Spasticity Scale—88 (MSSS- 88), Patient Reported Impact 
of Spasticity Measure (PRISM) and Leeds Spasticity Scale (LSS) have 
been validated in MS, spinal cord injury and stroke, respectively.6–8
To date, no self- report measure of spasticity has been developed 
for patients with ALS. The aim of this study was to develop a robust 
and reliable patient reported measure of spasticity for ALS.
2  | METHODS
The study comprised qualitative and questionnaire stages to de-
velop and validate the measure, followed by development of a model 
of spasticity, disability and quality of life. This work was part of the 
Trajectories of Outcomes in Neurological Conditions (TONiC) study, 
which is examining factors influencing quality of life over time in 
several neurological conditions. All participants received written in-
formation, and informed consent was obtained prior to enrolment 
into the study. Ethical approval was granted from the relevant local 
research committees (reference 11/NW/0743).
2.1 | Qualitative stage
Patients with confirmed ALS were invited to take part in one- to- one, 
semi- structured interviews at the Walton Centre, Liverpool. All pa-
tients were assessed for the presence of spasticity by a neurologist 
(CAY). A purposeful- sampling technique9 of patients with a wide 
range of spasticity level and distribution, disability, age and disease 
duration was employed to ensure that the data obtained at the in-
terviews reflected a comprehensive patient experience of spasticity.
A checklist of topic areas was drawn from extant literature on pa-
tient experience of spasticity in multiple sclerosis and spinal cord in-
jury. New topics based on the early responses of ALS patients were 
explored and added to the checklist. The same interviewer (KM) was 
used throughout. All interviews were recorded and transcribed ver-
batim. Thematic analysis was carried out during the course of the 
Results: A total of 465 patients (mean age 64.7 years (SD 10), 59% male) with ALS 
participated. Spasticity was reported by 80% of subjects. A pool of 71 items repre-
senting main themes of physical symptoms, negative impact and modifying factors 
was subject to an iterative process of item reduction by Rasch analysis resulting in a 
20- item scale—the Spasticity Index for ALS (SI- ALS)—which was unidimensional and 
free from differential item functioning. Moderate correlations were found with LSS 
and NRS- spasticity. Incorporating the latent estimate of spasticity into a path model, 
greater spasticity reduced quality of life and motor function; higher motor function 
was associated with better quality of life.
Conclusions: The SI- ALS is a disease- specific self- report scale, which provides a ro-
bust interval- level measure of spasticity in ALS. Spasticity has a substantial impact on 
quality of life in ALS.
K E Y W O R D S
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interviews and the list of themes emerged. The interviews were 
stopped once theme saturation was achieved. A list of questionnaire 
items retaining original participants’ wording was generated to re-
flect the main themes and subthemes.
A questionnaire containing 71 items was drafted and subjected 
to a cognitive debriefing with another set of ALS patients in outpa-
tient clinics. Their feedback was used to modify the format, layout 
and wording of some of the questions. Expert opinion regarding the 
content of the questionnaire was also sought from the multidisci-
plinary team members working with ALS patients including neurol-
ogists, rehabilitation consultants, physiotherapists and specialist 
nurses.
A Likert- style response option with four options of “strongly dis-
agree,” “disagree,” “agree” and “strongly agree” was chosen. There 
was an introductory question (“Have you experienced stiffness, 
tightness, spasms or cramps in any muscles including your legs, arms, 
trunk, neck and throat in the last 2 weeks?”) at the beginning of the 
scale. If participants answered “No,” they were instructed to skip the 
scale.
2.2 | Questionnaire stage
A questionnaire pack containing the 71- item draft together with 
other measures was mailed to patients with clinically confirmed ALS 
recruited at thirteen UK neuroscience centres over a 2- year period. 
The participants were instructed that the questionnaire should rep-
resent their perceptions and experience; those with severe physi-
cal disability could have assistance from care givers such as page 
turning or acting as a scribe. Patients with cognitive impairment or 
Frontotemporal Dementia (FTD) were not eligible for inclusion. Data 
from this development sample were subject to Rasch analysis with 
a view to producing a shortened scale, which was administered to a 
new, larger validation sample of patients with ALS.
Information on demographic characteristics including age, sex, 
disease type and duration was also collected. For external validation 
purposes, the following measures were included in the pack:
1. An 11-point numerical rating scale (NRS) for spasticity with 
anchors of “no spasticity” and “worst possible spasticity in the 
last 2 weeks.” The NRS has been previously validated in epi-
demiological studies on spasticity in MS.10
2. Leeds Spasticity Scale (SRSS) Scale for Stroke is an 8-item scale, 
which was developed and validated in patients with stroke-re-
lated spasticity.8
3. Amyotrophic Lateral Sclerosis—Functional Rating Scale—Revised 
(ALSFRS-R) is a validated measure of disability in ALS.11 It has 
been described as multidimensional with a recommendation that 
it is reported as a profile of bulbar, motor function and respiratory 
domains, rather than a total score.12
4. World Health Organization quality of life assessment (WHOQOL-
BREF) produces scores for four domains related to quality of life: 
physical health, psychological, social relationships and 
environment.13
5. Patients were asked to report if they suffer from the loss of emo-
tional control (emotional lability).
Non- responders were contacted by phone after 2- 4 weeks. 
Retest questionnaire was sent to a randomly selected proportion 
of patients 2 weeks after receiving the first questionnaire. Test- 
retest reliability was examined by differential item functioning 
(DIF) by time on all who completed the retest, and by concordance 
correlation coefficient (CCC)14,15 on those respondents who in-
dicated that there had been no change in their spasticity. CCC 
was rated using the Landis and Koch benchmarks: 0- 0.20 “slight,” 
0.21- 0.4 “fair,” 0.41- 0.60 “moderate,” 0.61- 0.8 “substantial” and 
above 0.81 “almost perfect” consistency.16 Absolute reliability 
was determined through the Standard Error of Measurement 
(SEM) and the Smallest Detectable Change (SDC). SEM is calcu-
lated	as	SEM	=	SD	all	testing	scores	×	√	(1-ICC).17 SDC represents 
the minimal change that a patient must show on the scale to en-
sure that the observed change is real and not just measurement 
error	and	was	calculated	as	1.96	×	√2	×	SEM	where	1.96	derives	
from the 95% CI.18
2.3 | Rasch analysis
The internal validity of the scale was investigated using the Rasch 
model, a probabilistic measurement model that is now widely used 
in the health and social sciences.19 Detailed description of the 
process of Rasch analysis can be found elsewhere.20 In summary, 
Rasch analysis is an iterative process, which tests whether the pat-
tern of responses meets the requirements of the Rasch model. In 
order for the scale to meet model expectations, the following must 
be satisfied:
1. Fit to the Rasch model (non-significant total chi-square and 
individual item chi-square statistic)
2. Ordered thresholds
3. Individual item fit residual ± 2.5
4. Unidimensionality of the scale confirmed if <5% of the independ-
ent t-tests are found significant
5. Differential item functioning (DIF) absent for age, sex and disabil-
ity status
6. Reliability (person-item separation index and Cronbach’s Alpha 
>0.85)
7. The absence of local item dependence
2.4 | Model
Given fit to the Rasch model, the SI- ALS can be transformed to 
an interval level metric and could be used in parametric analyses 
such as path analysis. Thus, a simple illustrative model was postu-
lated whereby the impact of spasticity (SI- ALS) upon quality of life 
(WHOQOL- BREF Psychological) is partially mediated by motor func-
tion (ALSFRS- R Motor). The influences of age, gender and onset type 
on this model were examined.
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3  | RESULTS
3.1 | Qualitative stage
Eleven patients (seven males) took part in the interview stage. The 
age range was 40- 81 years (median 51) and seven had limb, three 
bulbar and one respiratory onset of the disease.
The main themes were physical symptoms, negative impact and 
modifying factors. Physical symptoms were muscle stiffness, spasms 
and consequences (pain and discomfort). Negative impact was re-
ported on mobility, activities of daily living, social relationships, sleep 
and mood. Particularly distressing was bulbar spasms, characterized 
by sudden laryngeal closure and in the most extreme cases causing 
interference with breathing. None of the patients reported positive 
effects of spasticity on mobility or transfers.
Among modifying factors, heat, massage, relaxation and anti- 
spasticity medication were found to relieve spasticity. Factors that 
worsened or triggered spasticity were sudden movements, writing, 
stretching, cold, fatigue and exercise. Bulbar spasms occurred unpro-
voked or were triggered by yawning, laughing, speaking and eating. 
Further results of the qualitative study are described elsewhere.1
3.2 | Questionnaire stage
3.2.1 | Expert panel and cognitive debriefing
The multidisciplinary panel of clinicians with experience of ALS care 
endorsed the items as relevant to spasticity. The draft questionnaire 
was completed face- to- face with a researcher by 17 patients, to en-
sure the items had face validity and to identify any ambiguities with 
regard to the instructions, wording and layout.
3.2.2 | Sample characteristics
A total of 465 patients returned the questionnaire packs (response 
rate 51.6%). The mean age was 64.7 years (SD 10), and 278 (59%) 
were male (Table 1). Mean disease duration was 30 months. Limb 
onset was most common (60%), followed by Bulbar onset (24.7%), 
and 15.3% had unclassified onset type. There was no difference 
in onset type across years (chi- square 1.0; P = .580). The sam-
ple was representative of wide range of physical disability with 
ALSFRS- R Bulbar 0- 12, Motor Function 0- 24 and Respiratory 
1- 12. Just over a fifth (22.5%) reported no spasticity based on 
NRS- spasticity responses. A total of 178 participants completed 
the initial 71- item draft scale (development cohort), and a further 
287 patients completed the 20- item reduced item set (validation 
cohort).
3.2.3 | Rasch analysis
Initial fit of the 71- item draft scale to the Rasch model was poor. 
A substantial breach of the local independence assumption was 
observed, with residual correlations showing many clusters of 
variables as close replicas. Each cluster was considered, and the 
item with the best fit or absence of DIF was retained. An iterative 
phase of item reduction led to 20 items with satisfactory overall 
fit but some low levels (<0.2) of local response dependency were 
still observed, relating to symptoms associated in the same region 
of the body, for example, “My lips go blue when I get spasms in my 
throat” and “I get spasms in my jaw when I cough.” Consequently 
a testlet solution (10 items + 10 items) was employed to minimize 
any cumulative effect of local response dependency upon fit and 
dimensionality. Data from the validation stage and the pooled data 
(n = 465) had good fit with application of this final solution to the 
Rasch model (Table 2).
No differential item functioning was observed for age, gender, 
marital status, onset type or year of data collection (ANOVA P > .05). 
Where any spasticity was reported, the person- item distribution 
was well targeted, with the mean of persons just below the average 
of the scale (Figure 1).
3.2.4 | Final questionnaire
All three domains identified at the qualitative stage were repre-
sented in the final 20- item Spasticity Index—ALS.
TABLE  1 Demographic data
Characteristics
Total sample n = 465
Age
Mean (SD) 64.7 (10)
Sex
Female (%) 187 (41)
Male (%) 278 (59)
Duration of disease (months)
Mean (SD) 30 (40)
Range 1- 295
ALSFRS- R median (range)
Bulbar 3 (0- 12)
Motor 9 (0- 24)
Respiratory 1 (1- 12)
Employment status
Full- time employment (%) 42 (9)
Medically retired (%) 109 (24)
Unemployed (%) 10 (2.2)
Part- time (%) 24 (5.2)
Retired (%) 254 (54.6)
Not working for other reasons (%) 13 (2.8)
Questionnaire completion
Independent (%) 283 (60.9)
With assistance 160 (34.4)
Not stated 22 (4.7)
SD, standard deviation.
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Simple addition of all 20 items to yield a total SI- ALS score (pos-
sible range 0- 60) yields a valid ordinal score for clinical measure-
ment. If an interval level metric is required for parametric analyses, 
this total score should be transformed using the transformation 
(Table S1). Reliability of the scale was 0.87, the Standard Error of 
Measurement was 2.7 and the Smallest Detectable Change was 
7.5. This represents 12.5% of the total scale width. The correlation 
between the Leeds Spasticity scale and the SI- ALS was 0.61. Over 
a quarter (27.5%) skipped the Leeds Spasticity Scale, indicating no 
spasticity, whereas 19.6% skipped the SI- ALS. There was an 80% 
agreement in the presence and absence of spasticity between the 
two scales (defined by their respective skip questions). A significant 
gradient was also observed across the Numeric Rating Scale with 
anchors of “No spasticity” and “Worst Possible Spasticity” (F 23.4; 
P < .001). About 92% of participants who reported spasticity on 
the NRS completed the SI- ALS. Test- retest reliability (Concordance 
Correlation Coefficient) among those that were stable was substan-
tial at 0.793 (CI: 0.632- 0.889).
A significant association was observed between the level of re-
ported spasticity from the SI- ALS and onset type, with limb onset 
showing higher levels of spasticity (Kruskal- Wallis chi- square 6.2 (df 2); 
P = .046); likewise by age, where those people aged 65 and under dis-
played higher levels of spasticity (Mann- Whitney U Z; P < .001). Higher 
SI- ALS scores were also observed in patients who reported emotional 
lability (Kruskal- Wallis chi- square 12.62 (df 2); P = .002).
3.2.5 | Model
Variables were entered into the model as Rasch- transformed inter-
val scale estimates. A Sobel- Goodman Mediation Test indicated that 
27.7% of the effect of spasticity upon quality of life was mediated 
through motor function, supporting a partial mediation. Adding age 
into the path model for identification purposes, the path model is 
shown to be an adequate representation of the data (chi- square 0.97 
(df1); P = .3258) (Figure 2). All paths were significant with the excep-
tion of age at P = .069, showing a trend where increasing age led to 
TABLE  2 Rasch analysis: SI- ALS development and relevant variables for path model
Scale Stage
Residual- based fit Chi- square fit Reliability Unidimensionality
Item SD Person SD Value P PSI Alpha t- test % 95% CI
71 item draft 
SI- ALS
2.232 3.161 923.3 <.001 0.928 0.969 25.0 22.1- 27.9
20 Items SI- ALS
Individual 1.689 1.969 167.8 <.001 0.892 0.891 10.8 7.2- 14.4
Stage 1 testlet 0.139 0.900 1.3 .862 0.858 0.910 4.17 0.3- 8.1
Stage 2 testlet 0.303 0.831 0.7 .942 0.804 0.843 4.85 1.9- 7.8
Testlet pooled 0.303 0.977 10.1 .432 0.820 0.862 4.95 2.6- 7.3
ALSFRS- R- Motor 0.386 0.906 15.6 .210 0.67 0.76 1.1 −	0.9-	3.2
WHOQoL- Bref Psychological 3.126 0.947 8.5 .748 0.79 0.75 4.4 2.4- 6.4
Ideal values 1 1 >.05 >0.70 >0.70 <5.0 LCI <5.0
Alpha, Cronbach’s Alpha; CI/LCI, (Lower) Confidence Interval; P, P value; PSI, Person Separation Index; SD, Standard Deviation; Testlet is where items 
are grouped 10 + 10 to remove the effects of local dependency.
F IGURE  1 Person- item distribution
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worse quality of life. The model confirmed the hypothesized rela-
tionships, in that greater spasticity reduced quality of life and motor 
function, and higher motor function was reflected in a better qual-
ity of life. A significant covariance (correlation) was also observed 
between spasticity and age, with greater spasticity associated with 
younger age. The total effect of the model showed that the motor 
scale of the ALSFRS- R dominated the impact upon quality of life.
The model also showed group invariance for onset type across 
most parameters, with the exception of the relationship between 
spasticity and motor disability for the unclassified onset group, and 
the covariance between spasticity and age, which was only signifi-
cant for the limb onset group (chi- square 4.62 (df 3) P = .2017).
4  | DISCUSSION
To authors’ knowledge, this is the first study to have investigated 
ALS patients’ experience of spasticity using mixed qualitative and 
quantitative methods resulting in the development of a patient- 
driven, interval- level measure of spasticity, which meets the highest 
standards of psychometric scale development. The SI- ALS compre-
hensively and accurately reflects patient experience as evaluated in 
a large cohort with ALS in the UK.
The study demonstrates that spasticity affects the majority of 
patients with ALS; however, despite its high prevalence there has 
been a paucity of research on its assessment and treatment.21 While 
spasticity measures have been previously validated in other neuro-
logical disorders (stroke, MS, spinal cord injury), such instruments 
may inadequately capture the experience of spasticity reported 
by the ALS patients for several reasons. First, the distribution and 
extent of spasticity differs significantly in ALS compared to other 
neurological disorders. For example, bulbar spasticity is reported in 
ALS, while it is rarely seen in other disorders. Secondly, ALS affects 
both lower and upper motor neurones; therefore, items pertaining 
to muscle weakness found in other scales could confound the mea-
surement of spasticity in ALS. Finally, items addressing the impact 
of spasticity are unique to ALS due to the complex relationship be-
tween physical symptoms and quality of life in ALS.22
4.1 | Strengths and limitations
The SI- ALS is a strictly unidimensional measure which gives the 
advantage of providing a single linear score of spasticity without a 
need for subscales. The raw scores provide a truly ordinal measure 
of spasticity, which can be converted to interval level measurement 
using the transformation table provided (on the proviso that there 
are no missing data). This facilitates the use of path analysis, as in 
the above example.
The measure requires the patient, or their scribe, to tick 20 items 
with a simple four- level Likert scale. Time and ease of administra-
tion of the scale is particularly relevant in ALS patients due to high 
levels of physical disabilities and fatigue.23 The scale items reflect 
patient language and experience, and the cognitive debriefs and val-
idation analysis showed high face validity and patient acceptability. 
In particular, participants reported satisfaction that bulbar spasticity 
was included, because for affected patients, bulbar spasticity was 
a profound symptom and they deplored its omission from generic 
measures or those developed for other conditions.
The study also has several limitations. Respondents’ spasticity 
was not clinically assessed by a physician and validated against the 
SI- ALS. This was considered unnecessary and conceptually inappro-
priate for several reasons. First, the aim of the SI- ALS was to develop 
a patient- centred outcome measure, which is based on the patient’s 
experience rather than a clinician’s observation of spasticity. As a 
result, the SI- ALS and clinical assessment should be viewed as com-
plementary rather than competing measures of spasticity. Secondly, 
previous studies have demonstrated that agreement between 
clinician- administered methods and patient report of spasticity is 
poor (r < .5) indicating that clinician’s assessment is by no means a 
“gold- standard” measure.4,5
4.2 | Future directions
The present study serves as a platform for further research into the 
complex interplay between spasticity, physical and psychosocial fac-
tors and quality of life in ALS. Given interval- level data, the SI- ALS 
provides an opportunity for advanced statistical modelling of quality 
F IGURE  2 The model showing the 
effects of spasticity, motor function and 
age on quality of life
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of life determinants, which would further our understanding of the 
biopsychosocial model of ALS. Further work is needed to determine 
the minimal clinically important difference of the scale, which could 
be utilized in clinical trials of anti- spasticity therapies. Finally, exter-
nal validation of SI- ALS against clinical and biomechanical measures 
of spasticity would be of interest, as data on patient and clinician 
agreement on spasticity severity in ALS are lacking.
5  | CONCLUSION
The SI- ALS is a brief and reliable patient reported outcome measure 
of spasticity designed for use by people with ALS. Its development is 
based on ALS patient experience of spasticity and is in line with the 
Food and Drug Agency (FDA) guidelines for scale development.24 
Given the scale satisfies the requirements of Rasch measurement, 
the SI- ALS provides an interval level measurement of spasticity, 
which is valid for parametric analysis. The scale has high reliability 
and can be used in all patients with ALS irrespective of age, sex, 
disease duration and type. It is free for use for academic users and 
non- profit organizations and can be obtained via contact with the 
authors.
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